Next-Generation Protein Sequencing - CEOCFO Magazine Interview with Rapid Novor Inc

KITCHENER, Ontario, Aug. 22, 2017 /PRNewswire-iReach/ -- Rapid Novor Inc, the world leader in the next-generation protein sequencing, today announces that Mingjie Xie, the CEO of Rapid Novor Inc, has been interviewed by CEOCFO Magazine's Senior Editor Lynn Fosse

The interview, included in the magazine's recent August 21st issue, covers a range of topics from the company's current monoclonal antibody sequencing service, the new mass spectrometry facility to the company's strategies going forward. They also explored the differentiators against competitions and talked about the pros and cons comparing with the DNA sequencing based technology. 

"We devoted ourselves to the development of the next-generation protein sequencing technologies and its application on antibody drug discovery and liquid biopsy." said Mr. Xie in the interview. "Going forward and long term that is the value Rapid Novor Inc will provide."

The full interview can be found at http://www.ceocfointerviews.com/interviews/RapidNovor17.htm

About Rapid Novor Inc

Rapid Novor Inc is a privately held biotechnology company that develops the next-generation protein sequencing technologies and solutions. Specializing in the field of mass spectrometry-based proteomics, the company has developed the technology to directly sequence the antibody proteins without the needs to access the cell line. The company's mission is to advance life science for better human health with next-generation protein sequencing. The company is headquartered in Kitchener, Ontario, Canada. For more information, visit www.rapidnovor.com.

Media Contact: Mingjie Xie, Rapid Novor Inc, +1 (519) 593-2260, mxie@rapidnovor.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 

SOURCE Rapid Novor Inc



2018

Tags

Biotechnology, Pharmaceuticals, New Products & Services


More by this company


Need Help